A Phase 2 interventional study of Synthamin-17 (10% amino acid solution) and Placebo (Hartmann's balanced crystalloid solution) in Acute Kidney Injury, sponsored by Australian and New Zealand Intensive Care Research Centre. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Australian and New Zealand Intensive Care Research Centre · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Acute Kidney Injury with a site in Australia — 3 open to participants now, 4 under way, none of them phase 3. Acute Kidney Injury · Australia.
Among the 23 studies in Acute Kidney Injury with a site in Australia, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 22nd registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →3 of the 23 studies in Acute Kidney Injury with a site in Australia are open now. Recruiting first, the newest first:
Uppsala University · Sites in Australia, Brazil, Canada and 7 more countries
Ages 0–16
Indiana University · Sites in Australia, United States, Argentina and 30 more countries
Ages 0 min–2 wk
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 4 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 208 across the 18 interventional studies, 2,000 across the 5 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.
Australian and New Zealand Intensive Care Research Centre has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
3 of the studies in Acute Kidney Injury with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07438262Australian and New Zealand Intensive Care Research CentreThe AminoECMO Pilot Trial | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Acute Kidney Injury with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Acute kidney injury (AKI) is a serious problem for patients in intensive care, especially those on life-support machines like ECMO (which helps the heart and lungs). More than half of these patients develop severe kidney problems that often require dialysis, and this greatly increases the risk of poor outcomes.
Doctors try to prevent AKI by treating the underlying illness, avoiding kidney-harming drugs, and carefully managing fluids. But these methods are mostly supportive - they don't actively improve kidney function.
Studies in surgical patients (especially heart and urology operations) show that giving amino acids before surgery can reduce the chance of developing AKI. A major clinical trial even found that this approach significantly lowered AKI rates in heart surgery patients.
Amino acids (the building blocks of protein) seem to boost kidney performance. When given through a drip or feeding tube, they increase blood flow to the kidneys and may "wake up" unused kidney capacity - a concept called "functional renal reserve." It's not yet clear whether amino acids help critically ill patients on ECMO. More research is needed to see if this promising strategy can improve kidney function and outcomes in the sickest patients.
Acute kidney injury (AKI) is common in critically ill patients, especially in those requiring extracorporeal membrane oxygenation (ECMO). AKI is associated with significant morbidity and mortality. The current management for the prevention of AKI is supportive, such as treating underlying causes, avoiding nephrotoxins, and optimising fluid status. Despite optimal care, more than half of ECMO patients develop severe AKI requiring renal replacement therapy (RRT), including 46% in venovenous (V-V) ECMO, and 61% in venoarterial (V-A) ECMO. Severe AKI is associated with significantly worse outcomes and higher mortality, and there is a strong need to identify therapies that can improve renal function in ECMO.
It has already been established that glomerular filtration rate (GFR) increases in response to (IV or enteral) protein administration. The precise mechanism for increased GFR is not completely understood, however recruitment of dormant renal function (called functional renal reserve RFR) has been hypothesised. Amino acid delivery is associated with a renal vasodilation mediated increase renal blood flow by >30%. Different metabolic, endocrine, and paracrine factors have been implicated. It has been suggested that recruitment of RFR could prevent or manage AKI.
Amino Acids Infusions and Preventing AKI The impact of amino acids on renal function has been investigated in clinical trials. This has predominantly occurred in the perioperative setting, in patients with stable renal function undergoing operations associated with a significant risk of developing an AKI. In cardiac surgery, several early-phase studies have demonstrated an improvement in measures of renal function with the perioperative infusion of amino acids. These findings are not isolated to the cardiac surgery population, which may have unique pathological mechanisms for AKI, as a recent pilot RCT in patients undergoing major urology surgery demonstrated a reduction in the incidence of postoperative AKI. Recently a large RCT published in the New England Journal of Medicine showed that the peri-operative administration of amino acids in patients undergoing cardiac surgery significantly decreased the incidence of AKI. Importantly, in a sub group analysis of 232 patients who underwent perioperative mechanical cardiac support, the rate of AKI was lower in the group randomized to amino acids: 44.6 vs 60.8% relative risk 0.73 (0.57-0.94 P=0.01 NNT =6) suggesting a potentially important benefit in this group.
Despite the increasing interest and quantity of research surrounding the association between amino acid infusion and kidney function, several unanswered questions remain. Firstly, although amino acid infusion has been demonstrated to reduce the incidence of AKI when administered before an insult, the impact on renal function in critically ill patients receiving ECMO therapy is unclear, particularly as the insult may have already started to occur prior to ECMO initiation. Secondly, several recent studies of high dose protein have suggested potential harm in patients randomised to a higher dose of protein (2.2g/kg/day vs \<1.2g/kg/day) when given over prolonged periods.
The intervention in this pilot differs as it is will commence \<24hours post ECMO initiation, and it is given short term only (up to 48 hours). It remains unclear if this will translate to improve renal and patient outcomes.
In summary, ECMO therapy is associated with an increased risk of acute kidney injury. The current management for prevention of AKI is supportive with no current therapies that can decrease the risk of AKI and improve clinical outcomes. Given the physiologically and clinically demonstratable impact of amino acid infusion on renal function, further research is logical and desirable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study drug within the intervention arm will be continually infused for up to 48 hours whilst the patient is on ECMO. The infusion rate will be set to 2g/kg/ideal body weight/day (to a maximum of 100g). Patients enrolled into the control arm will be continually infused with a placebo for up to 48 hours whilst on ECMO.
Dietary Supplement: Synthamin-17 (10% amino acid solution)
Participants allocated to the control group will receive placebo comprised of Hartmann's balanced crystalloid solution (compound sodium lactate) to a maximum of 500mls and 48-hours.
Other: Placebo (Hartmann's balanced crystalloid solution)
First time comparing amino acid to placebo for prevention of acute kidney injury in patients receiving extracorporeal membrane oxygenation
Participants allocated to the control group will receive placebo comprised of Hartmann's balanced crystalloid solution (compound sodium lactate) to a maximum of 500mls and 48-hours.
The number of patients who received AA infusion within 24 hours of being randomised in the trial after ECMO initiation.
Participants randomised to the Intervention Group who received AA infusion within the 24 hour study time frame.
Time frame: 24 Hours from randomisation
Number of hours post randomisation that AA infusion was commenced in the intervention group
Date and time of randomisation and date and time that AA infusion was commenced
Time frame: Up to 24 hours post randomisation, or will be recorded as a Protocol Deviation
Number of patients who received AA infusion in the Intervention Group
The total number of participants randomised to the Intervention Group who received AA infusion
Time frame: Up to 48 hours from randomisation
Number of patients who received placebo in the control group
The number of participants randomised to the Control Group who received placebo
Time frame: Up to 48 hours post randomisation
Mean duration of AA infusion
What was the mean duration of AA infusion in participants who received it?
Time frame: Up to 48 hours post randomisation
Enrolment Rate
How many participants were enrolled in the trial from the eligible population?
Time frame: Up to 7 days from commencement of ECMO
Number of Protocol Deviations
How many total Protocol Deviations were recorded?
Time frame: Up to 7 days post commencement of ECMO
Mortality - in ICU and in hospital
Patients who died before being discharged from ICU or Hospital
Time frame: Participants discharge from ICU and Hospital
Urine output measured over 48 hours post the start of the AA or placebo infusion
Hourly urine output measures
Time frame: From initiation of AA or placebo infusion
Serum creatinine measured over 48 hours post the start of the AA and placebo infusion
Serum creatinine measures from bloods taken at specified times
Time frame: Blood sampling at Baseline, Day 1, Day 3, and Day 7
Urinary Neutrophil Gelatinase-associated lipocalin (NGAL) measured over 48 hours post the start of the AA and placebo infusion
Urinary NGAL processed from urine samples at pre-specified times
Time frame: Urine sampling taken at Baseline, Day 1, Day 3, and Day 7
Urine albumin/creatinine ratio (ACR) measured over 48 hours post the start of the AA and placebo infusion
ACR processed from urine samples collected at pre-specified times
Time frame: Urine sampling at Baseline, Day 1, Day 3, and Day 7
Urinary electrolytes measured over 48 hours post the start of the AA and placebo infusion
Urinary electrolytes processed from samples taken at pre-specified times
Time frame: Urine sampling at Baseline, Day 1, Day 3, and Day 7
Maximum severity of AKI up to day 7 (defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria)
The KDIGO will be assessed from serum creatinine and urine output
Time frame: Assessed at Day 1, Day 3, and Day 7 from randomisation
Duration of Acute Kidney Injury (AKI)
If AKI is present how long does it persist?
Time frame: Up to Day 30 post randomisation
Occurrence of acute kidney disease (AKD) (defined by the Acute Dialysis Quality Initiative - ADQI criteria)
Calculation of ADQI from serum creatinine, urine output and glomerular filtration rate
Time frame: Up to Day 7 from randomisation
New onset renal replacement therapy (RRT) during ECMO
Was RRT commenced for AKI while participant was receiving ECMO?
Time frame: From randomisation to cessation of ECMO flow
Plan to share: Yes — The management committee support the view of the international committee of medical journal editors and the world health organisation (WHO) with reference to the ethical obligation to responsibly share data acquired by interventional clinical trials. At the conclusion of the study, the management committee will consider requests from researchers who provide a methodically sound confidential scientific proposal as per the data sharing policy set out in the ANZIC-RC terms of reference. Only de-identified data will be shared and all requests for data must comply with the ethical, regulatory, and legislative requirements governing their jurisdiction.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Supporting information will be available from October 2026, and there will be no specified end date that this information can be accessed.
Access criteria: The Study Protocol and Statistical Analysis Plan will both be available on the Monash ANZIC-RC site from October 2026 onward.
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Aug 2027, 18 months later.
Of 39 non-industry phase 2 interventional studies under Acute Kidney Injury, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 42. This study's planned 18 months is below that.
Counting every sponsor, half of 57 studies reached it within 29 months; a quarter within 16 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amino-acid, glucose, and electrolyte solution
Australian and New Zealand Intensive Care Research Centre